ILAE MRI Recommendations, CPAP in OSA and MCI, Lemborexant Positive for Insomnia
Neurology News Network for the week ending June 15, 2019.
PUBLISHED June 15, 2019
This week, Neurology News Network covered the International League Against Epilepsy's new set of recommendations for the use of MRI in epilepsy, the findings from the Memories 1 trial regarding CPAP's impact on cognitive function in those with mild cognitive impairment, and the recently announced pooled data analysis of lemborexant in patients with insomnia (transcript below).
Welcome to Neurology News Network. I’m Alicia Bigica.Let’s get into the news from this week.
The International League Against Epilepsy’s Neuroimaging Task Force has published a new set of recommendations that provide guidance for the use of structural MRI in patients with epilepsy, including how to identify candidates for MRI, the minimum prerequisites for an MRI protocol, how MR images should be evaluated, and how lesion detection can be optimized.
The Task Force, which operated from 2013 through 2017, sought to improve the employment of MRI capabilities in the treatment of epilepsy, noting that the “use of MRI are variable worldwide and may not harness the full potential of recent technological advances for the benefit of people with epilepsy.”
This week, the NeurologyLive team was on-site in San Antonio, Texas for the SLEEP 2019 Annual Meeting, where findings from the Memories 1 clinical trial were presented. Data showed that adherence to continuous positive airway pressure, or CPAP, therapy is associated with a significant improvement in cognitive function in older adults with mild cognitive impairment and obstructive sleep apnea.
Given the positive results, the investigators have initiated Memories 2, a larger and more adequately powered study to both confirm and further extend the findings from the initial cohort.
Results of an analysis of 2 phase 3 clinical trials demonstrated a significant decrease in the severity of insomnia symptoms in patients treated with lemborexant, an investigational dual antagonist of the orexin OX₁ and OX₂ receptors.
Results from the SUNRISE-1 and SUNRISE-2 studies were used to conduct the symptom severity analysis, which ultimately revealed that roughly one-third of patients randomly assigned to either lemborexant 5-mg or 10-mg experienced a significant decline in their score on the Insomnia Severity Index, placing them below the threshold for clinically important insomnia.
For more direct access to expert insight, head to neurologylive.com. This has been Neurology News Network. Thanks for watching.